LGALS3 and in situ carcinoma: Immunofluorescent staining for p-mTOR revealed a significantly higher number of cells expressing mTOR in the kidneys of the CIS-treated Gal-3 wild-type mice (Figure 9B,E) than in the CIS-treated Gal-3 KO mice (p < 0.001) (Figure 9D,E).